VMAT technique enables concomitant radiotherapy of prostate cancer and pelvic bone metastases

Acta Oncologica

Volumn 54, Issue 6, 2015, Pages 847-853

  Kiljunen, Timo ^a   Kangasmäki, Aki ^a   Aaltonen, Aili ^a   Kairemo, Kalevi ^a   Partanen, Kaarina ^a   Joensuu, Greetta ^a   Alanko, Tuomo ^a   Vaalavirta, Leila ^a   Joensuu, Timo ^a  

^a Docrates Oncology Clinic   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE METASTASIS; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; HISTOGRAM; HUMAN; MALE; PELVIC GIRDLE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOTHERAPY EQUIPMENT; SEMINAL VESICLE; VOLUMETRIC MODULATED ARC THERAPY; BONE NEOPLASMS; COMPUTER ASSISTED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; MIDDLE AGED; ORGANS AT RISK; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION DOSE; RADIATION RESPONSE; RECTUM; RETROSPECTIVE STUDY; SECONDARY; TIME; VERY ELDERLY;

AGED, 80 AND OVER; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; ORGANS AT RISK; PELVIC BONES; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84929320816     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.962665     Document Type: Article

References (21)

1. Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: Identifying prognostic groups using recursive partitioning. JUrol 2003;169:164-9
2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T,.et al. EAUguidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467-79
3. Sweeney C, Chen Y, Carducci M, Liu G, Jarrard D, Eisen[3] berger M,.et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase IIIrandomized trial. JClin Oncol 2014;32:5s (suppl; abstr LBA2).
4. Oefelein MG. Prognostic significance of obstructive uropathy in advanced prostate cancer. Urology 2004;63:1117-21
5. Perez CA, Cosmatos D, Garcia DM, Eisbruch A, Poulter CA. Irradiation in relapsing carcinoma of the prostate. Cancer 1993;71:1110-22
6. Fogarty GB, Ng D, Liu G, Haydu LE, Bhandari N. Volumetric modulated arc therapy is superior to conventional intensity modulated radiotherapy-a comparison among prostate cancer patients treated in an Australian centre. Radiat Oncol 2011;6:108
7. Aznar MC, Petersen PM, Logadottir A, Lindberg H, Korreman SS, Kjaer-Kristoffersen F,.et al. Rotational radiotherapy for prostate cancer in clinical practice. Radiother Oncol 2010;97:480-4
8. Pesce GA, Clivio A, Cozzi L, Nicolini G, Richetti A, Salati E,.et al. Early clinical experience of radiotherapy of prostate cancer with volumetric modulated arc therapy. Radiat Oncol 2010;5:54
9. Clark GM, Popple RA, Young PE, Fiveash JB. Feasibility of single-isocenter volumetric modulated arc radiosurgery for treatment of multiple brain metastases. Int JRadiat Oncol Biol Phys 2010;76:296-302
10. Bignardi M, Cozzi L, Fogliata A, Lattuada P, Mancosu P, Navarria P,.et al. Critical appraisal of volumetric modulated arc therapy in stereotactic body radiation therapy for metastases to abdominal lymph nodes. Int JRadiat Oncol Biol Phys 2009;75:1570-7
11. Kuijper IT, Dahele M, Senan S, Verbakel WF. Volumetric modulated arc therapy versus conventional intensity modulated radiation therapy for stereotactic spine radiotherapy: A planning study and early clinical data. Radiother Oncol 2010;94:224-8
12. Macdougall ND, Dean C, Muirhead R. Stereotactic body radiotherapy in prostate cancer: Is rapidarc a better solution than cyberknife?. Clin Oncol (RColl Radiol) 2014;26:4-9
13. Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A,.et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN? prostate cancer: Results of a matched analysis. Eur Urol 2011;59:832-40
14. von Eyben FE, Kairemo K. Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun 2014;35:221-30
15. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury. Int JRadiat Oncol Biol Phys 2010;76:S123-9
16. Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU. Radiation dose-volume effects of the urinary bladder. Int JRadiat Oncol Biol Phys 2010;76:S116-22
17. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A,.et al. Use of normal tissue complication probability models in the clinic. Int JRadiat Oncol Biol Phys 2010;76:S10-9
18. Lawton CA, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C,.et al. RTOGGUradiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int JRadiat Oncol Biol Phys 2009;74:383-7
19. Yoo S, Wu QJ, Lee WR, Yin FF. Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes. Int JRadiat Oncol Biol Phys 2010;76:935-42
20. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A,.et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int JRadiat Oncol Biol Phys 2008;70:1124-9
21. Kairemo K, Rasulova N, Kiljunen T, Partanen K, Kangasmäki A, Joensuu T. PET/CT dose planning for volumetric modulated arc radiation therapy (VMAT)-comparison with conventional approach in advanced prostate cancer patients. Curr Radiopharm 2014 (in press).